YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination.

Authors

• James W Smithy
• Victoria Ciallella
• Claire Thant
• Hannah L Kalvin
• Jaykumar Thumar
• Suresh G. Nair MD, Lehigh Valley Health NetworkFollow
• Alexander Noor Shoushtari
• Parisa Momtaz
• Monica F Chen
• Katherine S Panageas
• Benjamin D Greenbaum
• Neeman Mohibullah
• Michael A Postow

Publication/Presentation Date

3-31-2026

Volume

24

Issue

3.5

ISSN

1540-1413

Published In/Presented At

Smithy, J. W., Ciallella, V., Thant, C., Kalvin, H. L., Thumar, J., Nair, S., Shoushtari, A. N., Momtaz, P., Chen, M. F., Panageas, K. S., Greenbaum, B. D., Mohibullah, N., & Postow, M. A. (2026). YIA26-003: Characterizing the Peripheral T-Cell Repertoire in Patients With Unresectable Melanoma Treated With the IDO- and PD-L1 Targeted Peptide Vaccine IO102-IO103 and Nivolumab-Relatlimab Fixed-Dose Combination. Journal of the National Comprehensive Cancer Network : JNCCN, 24(3.5), YIA26-003. https://doi.org/10.6004/jnccn.2025.7450

Disciplines

Medicine and Health Sciences

PubMedID

41911867

Department(s)

Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article